文献速递其他结缔组织病

静脉注射免疫球蛋白作为特发性炎症性肌病一线治疗的初步研究

Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

这项研究者发起的2期开放标签试验纳入20例新诊断、活检证实的特发性炎症性肌病患者,病程小于9个月,排除包涵体肌炎和既往免疫抑制剂使用者,给予IVIg单药治疗9周。主要终点为2016年ACR/EULAR总改善评分至少中度改善,19例可分析患者中8例(42.0%;95%CI:19.6,64.6)达到该终点,其中6例在3周内改善。7例因疗效不足需救援治疗并提前终止研究,发生3例严重不良事件,包括1例肺栓塞。

要点

  • IVIg单药一线治疗9周可使42.0%的特发性炎症性肌病患者达到至少中度改善。
  • 多数应答者在3周内即出现临床改善,提示起效较快。
  • 7例因疗效不足需救援治疗,3例严重不良事件中含1例肺栓塞。

核心结论

  • 一线IVIg单药治疗使近半数特发性炎症性肌病患者达到至少中度改善,且多数应答者临床反应迅速。

研究设计与样本

  • 研究者发起的2期开放标签研究,纳入20例新诊断、活检证实的特发性炎症性肌病成人患者,病程小于9个月,排除IBM和既往免疫抑制剂使用者。
  • 标准方案为IVIg(Privigen)单药治疗9周:负荷剂量2 g/kg体重,随后两次维持剂量1 g/kg体重,间隔3周。

主要发现

  • 纳入患者包括DM 9例、免疫介导坏死性肌病6例、非特异性肌炎/重叠肌炎4例、抗合成酶综合征1例。
  • 1例因肌无力轻微存在天花板效应被排除分析。
  • 8/19例(42.0%;Clopper-Pearson 95%CI:19.6,64.6)在9周时达到至少中度改善,其中6例在3周内改善。
  • 7例因疗效不足需救援治疗并提前终止研究。
  • 发生3例严重不良事件,其中1例为肺栓塞。

关键数值与推荐

  • 主要终点为2016年ACR/EULAR总改善评分至少中度改善的患者数。

临床怎么用

  • 对于新诊断、病程小于9个月且排除IBM的特发性炎症性肌病患者,可考虑IVIg单药作为一线治疗选择。
  • 治疗9周内应评估疗效,多数应答者在3周内出现改善。
  • 需监测严重不良事件,包括肺栓塞。

局限性

  • 本研究为开放标签、单臂、小样本初步研究,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We explored efficacy and safety of IVIg as first-line treatment in patients with an idiopathic inflammatory myopathy. METHODS: In this investigator-initiated phase 2 open-label study, we included 20 adults with a newly diagnosed, biopsy-proven idiopathic inflammatory myopathy, and a disease duration of less than 9 months. Patients with IBM and prior use of immunosuppressants were excluded. The standard treatment regimen consisted of IVIg (Privigen) monotherapy for 9 weeks: a loading dose (2 g/kg body weight) and two subsequent maintenance doses (1 g/kg body weight) with a 3-week interval. The primary outcome was the number of patients with at least moderate improvement on the 2016 ACR/EULAR Total Improvement Score. Secondary outcomes included time to improvement, the number of patients requiring rescue medication and serious adverse events. RESULTS: We included patients with DM (n = 9), immune-mediated necrotizing myopathy (n = 6), non-specific myositis/overlap myositis (n = 4) and anti-synthetase syndrome (n = 1). One patient was excluded from analyses because of minimal weakness resulting in a ceiling effect. Eight patients (8/19 = 42.0%; Clopper-Pearson 95% CI: 19.6, 64.6) had at least moderate improvement by 9 weeks. Of these, six reached improvement by 3 weeks. Seven patients required rescue medication due to insufficient efficacy and prematurely ended the study. Three serious adverse events occurred, of which one was pulmonary embolism. CONCLUSION: First-line IVIg monotherapy led to at least moderate improvement in nearly half of patients with a fast clinical response in the majority of responders. TRIAL REGISTRATION: Netherlands Trial Register identifier, NTR6160.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford). 2021. PMID: 33099648. doi:10.1093/rheumatology/keaa459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。